Hebei Changshan Biochemical Pharmaceutical Valuation
Is 300255 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 300255 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 300255 (CN¥19.08) is trading below our estimate of fair value (CN¥22.53)
Significantly Below Fair Value: 300255 is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 300255?
Key metric: As 300255 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 300255's PS Ratio? | |
|---|---|
| PS Ratio | 16.6x |
| Sales | CN¥1.05b |
| Market Cap | CN¥17.54b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 18.5x |
| Enterprise Value/EBITDA | -22.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 300255's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.3x | ||
002755 Beijing Aosaikang Pharmaceutical | 7.7x | 13.6% | CN¥13.1b |
603858 Shandong Buchang Pharmaceuticals | 1.5x | n/a | CN¥17.9b |
600867 Tonghua Dongbao Pharmaceutical | 6.7x | 24.4% | CN¥16.4b |
600420 Shanghai Shyndec Pharmaceutical | 1.4x | 7.6% | CN¥16.1b |
300255 Hebei Changshan Biochemical Pharmaceutical | 16.6x | n/a | CN¥17.5b |
Price-To-Sales vs Peers: 300255 is expensive based on its Price-To-Sales Ratio (16.6x) compared to the peer average (4.3x).
Price to Sales Ratio vs Industry
How does 300255's PS Ratio compare vs other companies in the CN Pharmaceuticals Industry?
| 5 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
600664 Harbin Pharmaceutical Group | 0.6x | n/a | US$1.32b |
000411 Zhejiang Int'l GroupLtd | 0.2x | n/a | US$801.61m |
600781 FUREN Group PharmaceuticalLtd | 0.3x | n/a | US$66.91m |
002435 Changjiang Runfa Health Industry | 0.2x | n/a | US$63.75m |
| 5 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: 300255 is expensive based on its Price-To-Sales Ratio (16.6x) compared to the CN Pharmaceuticals industry average (3.6x).
Price to Sales Ratio vs Fair Ratio
What is 300255's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 16.6x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 300255's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Hunan Jiudian Pharmaceutical
CN¥12.2b
Researches, develops, produces, and sells pharmaceutical products in China and internationally.
300705
CN¥24.71
7D
-0.2%
1Y
5.1%
China Resources Double-Crane PharmaceuticalLtd
CN¥21.4b
China Resources Double-Crane Pharmaceutical Co.,Ltd.
600062
CN¥20.87
7D
-5.5%
1Y
11.1%
Hunan Jiudian Pharmaceutical
CN¥12.2b
Researches, develops, produces, and sells pharmaceutical products in China and internationally.
300705
CN¥24.71
7D
-0.2%
1Y
5.1%